179 related articles for article (PubMed ID: 18652658)
21. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project.
Niskanen L; Hedner T; Hansson L; Lanke J; Niklason A;
Diabetes Care; 2001 Dec; 24(12):2091-6. PubMed ID: 11723089
[TBL] [Abstract][Full Text] [Related]
22. New-onset diabetes and antihypertensive drugs.
Mancia G; Grassi G; Zanchetti A
J Hypertens; 2006 Jan; 24(1):3-10. PubMed ID: 16331092
[TBL] [Abstract][Full Text] [Related]
23. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis.
Psaty BM; Smith NL; Siscovick DS; Koepsell TD; Weiss NS; Heckbert SR; Lemaitre RN; Wagner EH; Furberg CD
JAMA; 1997 Mar; 277(9):739-45. PubMed ID: 9042847
[TBL] [Abstract][Full Text] [Related]
24. Update on the management of hypertension: do recent clinical trial results indicate a change in national recommendations for therapy?
Moser M
J Clin Hypertens (Greenwich); 2002; 4(6 Suppl 2):20-31. PubMed ID: 12461317
[TBL] [Abstract][Full Text] [Related]
25. [DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease].
Scheen AJ
Rev Med Liege; 2006 Oct; 61(10):728-32. PubMed ID: 17209507
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.
Wu HY; Huang JW; Lin HJ; Liao WC; Peng YS; Hung KY; Wu KD; Tu YK; Chien KL
BMJ; 2013 Oct; 347():f6008. PubMed ID: 24157497
[TBL] [Abstract][Full Text] [Related]
27. Comparative risk of new-onset diabetes mellitus for antihypertensive drugs in elderly: A Bayesian network meta-analysis.
Zhang J; Tong A; Dai Y; Niu J; Yu F; Xu F
J Clin Hypertens (Greenwich); 2019 Aug; 21(8):1082-1090. PubMed ID: 31241860
[TBL] [Abstract][Full Text] [Related]
28. The HOPE Study (Heart Outcomes Prevention Evaluation).
Sleight P
J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
[TBL] [Abstract][Full Text] [Related]
29. Evolving treatment options for prevention of cardiovascular events in high-risk hypertensive patients.
Deedwania P
J Clin Hypertens (Greenwich); 2007 Nov; 9(11):883-8. PubMed ID: 17978596
[TBL] [Abstract][Full Text] [Related]
30. Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey.
Mori Y; Nishikawa Y; Iizuka T; Zenimura N; Matsumoto T; Hiramatsu K; Komiya M
Drugs R D; 2011; 11(2):171-90. PubMed ID: 21679007
[TBL] [Abstract][Full Text] [Related]
31. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
Zeltner R; Poliak R; Stiasny B; Schmieder RE; Schulze BD
Nephrol Dial Transplant; 2008 Feb; 23(2):573-9. PubMed ID: 17984104
[TBL] [Abstract][Full Text] [Related]
32. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
Yusuf S
Am J Cardiol; 2002 Jan; 89(2A):18A-25A; discussion 25A-26A. PubMed ID: 11835907
[TBL] [Abstract][Full Text] [Related]
33. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care.
Vijan S; Hayward RA
Ann Intern Med; 2003 Apr; 138(7):593-602. PubMed ID: 12667032
[TBL] [Abstract][Full Text] [Related]
34. Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
Schädlich PK; Brecht JG; Rangoonwala B; Huppertz E
Pharmacoeconomics; 2004; 22(15):955-73. PubMed ID: 15449961
[TBL] [Abstract][Full Text] [Related]
35. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.
Curb JD; Pressel SL; Cutler JA; Savage PJ; Applegate WB; Black H; Camel G; Davis BR; Frost PH; Gonzalez N; Guthrie G; Oberman A; Rutan GH; Stamler J
JAMA; 1996 Dec; 276(23):1886-92. PubMed ID: 8968014
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors.
Mann JF
Presse Med; 2005 Oct; 34(18):1303-8. PubMed ID: 16269994
[TBL] [Abstract][Full Text] [Related]
37. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
Esnault VL; Ekhlas A; Nguyen JM; Moranne O
Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
[TBL] [Abstract][Full Text] [Related]
38. A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.
Wing LM; Reid CM; Ryan P; Beilin LJ; Brown MA; Jennings GL; Johnston CI; McNeil JJ; Macdonald GJ; Marley JE; Morgan TO; West MJ;
N Engl J Med; 2003 Feb; 348(7):583-92. PubMed ID: 12584366
[TBL] [Abstract][Full Text] [Related]
39. Adult hypertension: reducing cardiovascular morbidity and mortality.
Prescrire Int; 2005 Feb; 14(75):25-33. PubMed ID: 15751180
[TBL] [Abstract][Full Text] [Related]
40. Impact of ASCOT on hypertension treatment and guidelines in older adults.
Sheridan R; Baldwin N
Age Ageing; 2006 May; 35(3):214-7. PubMed ID: 16638764
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
